PMLiVE | Pharmaceutical industry news, articles, jobs, reports, …
Dec 23, 2021 · Iona Everson from PMGroup spoke to John Forni, Country Medical Director at Sanofi UK & Ireland, about the escalating challenges of treating chronic obstructive pulmonary disease (COPD) in the UK and how the government, NHS and industry can work together to …
PMLiVE | Pharmaceutical industry news, articles, jobs, reports, …
PMLiVE | Pharmaceutical industry news, articles, jobs, reports, advice ... ... News
Regeneron shares positive phase 3 results for Libtayo in high-risk …
20 hours ago · Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 C-POST trial has been comparing adjuvant treatment with the PD-1 inhibitor against placebo in patients ...
PME - Home
How AI and digital innovations can help agencies and pharma support HCPs in the fight against COVID-19 - PME Supplement August 2020. As the realities of COVID-19 hit and lockdown restrictions came into force around the world, agencies and pharma suddenly found themselves embracing AI and digital innovations at an accelerated rate.
PME - Articles - Pharmaceutical Market Europe
Dec 15, 2024 · Discover the latest articles published by PME. Pharmaceutical industry news, articles, jobs, reports, advice and services!
PME - PMLiVE
Pharmaceutical Market Europe – October 2024. Boehringer Ingelheim’s Ulrike Graefe-Mody on her career path; Driving launch excellence; Top trends coming out of ESMO 2024
October 2024 - Pharmaceutical Market Europe
Oct 15, 2024 · PME – Pharmaceutical Market Europe is a monthly print and digital title written by experienced journalists and high-profile pharma and healthcare experts.
About us - PMLiVE
DESIGN AND PRODUCTION. Hina Mistry – Designer Email: [email protected] Tel: +44 (0)1372 414 272. Anamaria Popescu – Front-End Developer Email: [email protected] Tel: +44 (0)1372 414 262
AbbVie and Simcere to advance multiple myeloma candidate in …
20 hours ago · AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for multiple myeloma. The companies have entered into an option to licence agreement for Simcere Zaiming’s SIM0500, a trispecific antibody currently in phase 1 clinical development in the US and China for …
PME Magazine
The explosive growth of Gen AI; Liberating patient pathways; Closing health equity gaps